Financial Associated Press, February 28 - Chen Baohua, deputy to the National People's Congress and Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) president, suggested that China's class 1 innovative drugs and class 2 improved new drugs could not be imitated, which has become the focus of the majority of pharmaceutical enterprises. There is a phenomenon of monopolizing the market for a long time after listing (even if the protection period of new drug patents has long expired), forming a monopoly price for sales, It is suggested to speed up the revision and improvement of the current relevant policies, endow China with the status of reference preparation of new drugs, create preconditions for the imitation of new drugs in China, and encourage the listing of generic drugs. For example, for China's class 1 innovative drugs that have been approved for listing and China's class 2 improved drugs that have clinical value / advantages, safety and effectiveness, directly endow them with the status of reference preparation.
© China Stock Market News